Stemline Therapeutics, Inc.

Targeting cancer at its root
developing novel drugs that attack Cancer Stem Cells

	The Company
	Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company developing novel oncology compounds that target cancer stem cells.

	Platform
	Stemline Therapeutics has developed a Discovery Platform called StemScreen^® to identify novel compounds that target and kill CSCs.

News
&
Events

6/10/2013
Stemline's SL-401 Receives Orphan Drug Designation for the Treatment BPDCN

5/31/2013
Stemline Therapeutics to Present at Jefferies 2013 Global Healthcare Conference

5/30/2013
Stemline Announces Presentations at the 2013 ASCO Annual Meeting